BACKGROUND RECOMMENDATIONS
|
|
- Melinda Webb
- 7 years ago
- Views:
Transcription
1 KAISER PERMANENTE OHIO ATRIAL FIBRILLATION Methodology: Evidence-Based Issue Date: 3-97 Champion: Cardiology Most Recent Updates: 9-03,12-05, 2-07, 1-09 Key Stakeholders: Cardiology, IM Next Update: 3-11 BACKGROUND Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, especially to the brain. Two basic strategies have evolved for reducing the risk of stroke in atrial fibrillation: cardioversion and antithrombotic therapy. This discussion will center on these two basic strategies. The vast majority of patients with atrial fibrillation have organic heart disease. Less than 10% of atrial fibrillation cases are defined as lone atrial fibrillation; (i.e., patients with atrial fibrillation without organic heart disease, hypertension or diabetes mellitus). Valvular heart disease accounts for 15% to 30% of the cases of atrial fibrillation; nonvalvular heart disease accounts for 50% to 80% with causes including coronary artery disease, cardiomyopathy, congenital heart disease, hypertension, and thyrotoxic heart disease. Most patients presenting to the physician's office or to the Emergency Department with atrial fibrillation do not require hospital admission. AF not occurring in a setting of reversible cause (e.g., myocardial infarction, pericarditis and cardiac surgery) can be classified in the following categories: new-onset AF, paroxysmal AF, persistent AF, and permanent AF. 1 New-onset AF is defined as AF not previously documented. Paroxysmal AF is if the arrhythmia terminates spontaneously not dependent upon pharmacologic or nonpharmacologic interventions. The duration of the paroxysmal AF is normally less then 24 to 48 hours. Paroxysmal AF may occur only once or may be recurrent. Persistent AF is defined as AF with duration of seven days or longer. Permanent AF is defined as long standing AF in which no further attempts will be made to restore or maintain sinus rhythm. The recommendations contained in this guideline can be followed for most patients without inpatient hospitalization. Cardioversion can be performed in an outpatient monitored setting. Anticoagulation with warfarin can be initiated and followed in outpatients. Acute myocardial infarction needs to be ruled out in few patients with atrial fibrillation. When uncertainty exists, contact the Cardiologist on-call. The use of electrical cardioversion in the outpatient monitored setting can be expected to decrease hospital admissions and shorten stays in monitored areas. RECOMMENDATIONS Rhythm Control vs. Heart Rate control Reasons for restoration and maintenance of sinus rhythm in patients with AF include relief of symptoms, prevention of embolism, and avoidance of cardiomyopathy. Conversion to and maintenance of sinus rhythm offers the theoretical advantages of reducing the risk of thromboembolism and consequently the need for chronic anticoagulation. Several recently published clinical trials (AFFIRM, RACE) have been completed with data suggesting no clear advantage of one approach over the other with similar outcomes in total mortality and ischemic stroke. New-Onset Atrial Fibrillation (see Figures 1 & 2)
2 When atrial fibrillation duration has been less than 48 hours, no anticoagulation is required and cardioversion can be performed. Rate control with beta blockers, calcium blockers, or digoxin is suggested to obtain a resting heart rate <100 before attempted chemical cardioversion with antiarrhythmic medications such as 1A drugs (e.g., quinidine, procainamide, disopyramide), or 1C drugs (propafenone, flecainide). Type 1C drugs should not be used in patients with prior myocardial infarction or with decreased left ventricular function. Emergency direct current cardioversion for new onset atrial fibrillation should be considered in hemodynamically unstable patients or patients with congestive heart failure or myocardial infarction with rapid ventricular response. After 48 hours, or if one is uncertain as to the duration of the new onset AF, the patient should be given warfarin therapy for at least 3 to 4 weeks at an INR of 2-3 and schedule for an elective cardioversion. During this period, rate control should be established with standard therapy including digoxin, calcium channel blockers, or beta blockers (see Fig 3). Hospitalization is not required in these patients when starting warfarin therapy to establish therapeutic levels. This can be accomplished in an outpatient setting. Recurrent Paroxysmal Atrial Fibrillation (See Fig. 3) For patients who experience brief or minimally symptomatic recurrences of paroxysmal AF, it is reasonable to avoid antiarrhythmic drugs unless troublesome symptoms occurs. Rate control and prevention of thromboembolism are appropriate in both situations. Recurrent Persistent Atrial Fibrillation (See Fig. 3) Defined as patient who have undergone at least 1 attempt to restore sinus rhythm and may remain in AF after its second occurrence with minimal or no symptoms. These patients should be treated with therapy for rate control and prevention of thromboembolism. Alternatively, those with symptoms favoring sinus rhythm should be treated with an antiarrhythmic agent (in addition to medications for rate control and anticoagulation) before cardioversion. Permanent Atrial Fibrillation (See Fig. 3) The treatment of permanent AF is given to patients in which sinus rhythm cannot be sustained after cardioversion of AF or when the patient and physician have decided to allow AF to continue without further efforts to restore sinus rhythm. It is important to maintain control of the ventricular rate and to use antithrombotic therapy, as outlined in TABLE 2 for all patients in this category. Preventing Thromboembolism (See Table 1) The rate of stroke in patients with AF is related to coexistent cardiovascular disease. Adjusted-dose oral anticoagulation (Warfarin) is more efficacious then aspirin for prevention of stroke in patients with AF. All patients with AF should be administered antithrombotic therapy (Warfarin or Aspirin), except those with lone AF, to prevent thromboembolism. Those with coumadin include those with an allergy to coumadin, recent surgery (6 weeks), proten c deficiency frequent falls especially those with a history of head trauma or fracture other than hip and pregnancy. The selection of antithrombotic agent (Warfarin or Aspirin) should be individualized based upon assessment of the absolute risks of stroke and bleeding and the relative risk and benefit for the particular patient (See TABLE 2). Chronic oral anticoagulant therapy (Warfarin) should be dose adjusted to achieve a target INR of 2 to 3 in patients at high risk of stroke, unless contraindicated. Aspirin in a dose of 325 mg daily may be used as an alternative in low-risk patients or in those with certain contraindications to oral anticoagulation. Oral anticoagulation with Warfarin is indicated for all patients with AF associated with rheumatic mitral valve disease or prosthetic heart valves (mechanical or tissue valves). The use of anticoagulation in those patients age 85+ or those with severe functional impairment needs to be tempered by clinical judgment, given the known risks of anticoagulation. Adapted from KP Southern California Page 2
3 Cardioversion Cardioversion is usually performed electively to restore sinus rhythm in patients with persistent AF. Cardioversion without prior anticoagulation may be attempted in patients with new-onset AF less then 24 hours or when acute AF produces hemodynamic instability in the form of angina pectoris, MI, shock, or pulmonary edema. Otherwise, anticoagulation with warfarin with an INR of 2-3 is recommended for 3 to 4 weeks before and after cardioversion for patients with AF of unknown duration or with AF for more then 48 hours. Asymptomatic patients with controlled atrial fibrillation of more than 24 hours duration who are considered for cardioversion do not require hospitalization for anticoagulant therapy. They can be treated with 3 weeks of warfarin therapy with INR of 2-3. After this treatment, they may have chemical or electrical cardioversion. Rate control should be attempted with beta blockers or calcium channel blockers. Digoxin used as monotherapy is a poor drug for rate control. Underlying etiologic mechanisms for atrial fibrillation must be investigated, such as thyrotoxicosis and congestive heart failure. The role of echocardiography in atrial fibrillation is to exclude anatomic disease. When history and physical exam suggest valvular, myocardial, or pericardial disease the study is indicated. It should not be used solely to determine left atrial size, which in itself does not predict the initial success of cardioversion. Chemical Cardioversion (see Table 2) Chemical cardioversion, if preferred to electrical cardioversion, may be attempted in an electrocardiographically monitored setting. This may be emergency room, telemetry unit, or other in or outpatient monitored area. Patients without ventricular dysfunction or ischemia are at low proarrhythmic risk. Electrical cardioversion is preferred by many physicians because of the risk of proarrhythmia associated with anti-arrhythmic agents. New regimens such as single dose oral flecainide at 300 mg exist to supplement or supplant the older regimens of quinidine and procainamide. Intravenous Ibutilide is an option in patients without cardiomyopathy but requires electrocardiographic monitoring for six hours after administration. Chemical cardioversion should be successful in 24 hours or less. After cardioversion, discharge to outpatient follow-up can usually be accomplished promptly in low risk patients and within 24 hours in high risk patients. Rate control is defined as a resting ventricular rate of atrial fibrillation < 110 beats/minute. Initial therapy with usual loading dose of digoxin mg followed by maintenance digoxin should be used in patients with rapid atrial fibrillation. Additional rate control should be accomplished with either beta blockers or calcium channel blockers. The calcium channel blockers most commonly used are dilitiazem or verapamil. Digoxin should not be pushed to high doses. Digoxin is not a good drug for rate control in atrial fibrillation, particularly during enhanced sympathetic states such as physical activity, because the rate control of digoxin is solely from vagotonic action. Once rate control is established, chemical cardioversion can be attempted with a 1A, 1C, or type III drug. If the patient should develop "torsade de pointes" (i.e., a rapid polymorphic ventricular tachycardia, or an exacerbation of ventricular ectopy secondary to the drug), the patient should be assessed and the drug stopped. A second drug could be tried. If chemical cardioversion with a 1A, IC or type III drug is not successful, electrical cardioversion should be attempted unless digitoxicity is suspected. In the patient with chronic atrial fibrillation, if the duration has exceeded 6 months, cardioversion is not usually recommended. A return to sinus rhythm is unlikely. Rate control should be established. Warfarin therapy should be continued for 4 weeks after successful cardioversion to normal sinus rhythm. Antiarrhythmic therapy may be continued for 6-12 months after successful conversion. Therapy should be reassessed after this time. Caution: Antiarrhythmic drugs may cause proarrhythmia and may lead to increased mortality rates. Adapted from KP Southern California Page 3
4 Table 1. Risk-Based Antithrombotic Therapy in Patients With Atrial Fibrillation Patient Features Recommended Antithrombotic Therapy Age < 60, no heart disease (Lone AF) Aspirin (325 mg per day) or no therapy Age < 60, heart disease but no risk factors* Aspirin (325 mg per day) Age 60, no risk factors* Aspirin (325 mg per day) Age 60, with diabetes or CAD Oral anticoagulation (INR ), addition of aspirin ( mg) per day is optional Age to 75, especially women Oral anticoagulation (INR = 2.0) Heart failure, LV ejection fraction 35%, Oral anticoagulation (INR ) thyrotoxicosis, and hypertension Rheumatic heart disease (mitral stenosis) Oral anticoagulation (INR or higher may be Prosthetic heart valves appropriate) Prior thromboembolism Persistent atrial thrombus on TEE * Risk factors for thromboembolism include heart failure, LV EF < 35%, history or hypertension. Table 2. Recommended Drugs for Pharmacological Cardioversion of Atrial Fibrillation Drug Route of Dosages Potential Adverse Effects Administration Amiodarone Oral Inpatient: g per day in divided dose until 10 g total, then mg per day maintenance or 30 mg/kg as single dose Intravenous/oral Oral Outpatient: mg per day divided dose until 10 g total, then mg per day maintenance 5-7 mg/kg over min, then g per day continuous IV or in divided oral doses until 10g total, then mg per day maintenance Creatinine Clearance Dose (ml/min) > <20 (mcg BID) Contraindicated Flecainide Oral mg Intravenous mg/kg over min Propafenone Oral mg Intravenous mg/kg over min Quinidine Oral g in divided doses over 6-12 h, usually with a rate-slowing drug Hypotension, bradycardia, QT prolongation, tosade de pointes (rare), GI upset, constipation, phlebitis (IV) QT prolongation, torsade de pointes; adjust dose for renal function, body size, and age Hypotension, rapidly conducting atrial flutter Hypotension, rapidly conducting atrial flutter QT prolongation, tosade de pointes, GI upset, hypotension Adapted from KP Southern California Page 4
5 Figure 1. Treatment Algorithm New-Onset Atrial Fibrillation New-Onset AF Paroxysmal Persistent 1. No therapy needed unless severe symptoms (e.g., hypotension, HF, angina) 2. Treat associated HD Yes Accept permanent AF No as needed Consider Antiarrhythmic drug therapy Cardioversion Long-term antiarrhythmic drug therapy unnecessary * The use of anticoagulation in those patients age 85+ or those with severe functional impairment needs to be tempered by clinical judgment, given the known risks of anticoagulation. Adapted from KP Southern California Page 5
6 Figure 2. Antiarrythmic Drug Selection for Rhythm Heart Disease No or minimal Yes Flecainide Propafenone Sotalol CHF or LVEF < 0.35% CAD Hypertension Amiodarone, Amiodarone, Sotalol LVH 1.4 cm Yes No Disopyramide Procainamide Quinidine Amiodarone Amiodarone Flecainide Propafenone Consider nonpharmacological options, i.e. AV ablation, AV nodal ablation with permanent pacemaker, Focal RFA Disopyramide Procainamide Quinidine Amiodarone Sotalol Disopyramide Procainamide Quinidine Adapted from KP Southern California Page 6
7 Figure 3. Treatment Algorithm: Recurrent and Permanent Atrial Fibrillation Recurrent Paroxysmal AF Recurrent Persistent AF Permanent AF Minimal or no Symptoms Disabling symptoms in AF Minimal or no Symptoms Disabling symptoms in AF Anticoagulation No drug for prevention of AF Antiarrhythmic drug therapy Electrical cardioversion Continue anticoagulation and therapy to maintain sinus rhythm * The use of anticoagulation in those patients age 85+ or those with severe functional impairment needs to be tempered by clinical judgment, given the known risks of anticoagulation. Adapted from KP Southern California Page 7
8 SOURCES 1. Kaiser Permanente, Southern California. Guideline for Atrial Fibrillation Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38: Van Gelder IC, Hagens VE, et al. A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation. NEJM. 2002; 347: Adapted from KP Southern California Page 8
Atrial Fibrillation Peter Santucci, MD Revised May, 2008
Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial fibrillation (AF) is an irregular, disorganized rhythm characterized by a lack of organized mechanical atrial activity. The atrial rate is
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationRecurrent AF: Choosing the Right Medication.
In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/89015.htm Recurrent AF: Choosing the Right Medication. Basamad Z. * Assistant Professor, Department
More informationAtrial fibrillation (AF) care pathways. for the primary care physicians
Atrial fibrillation (AF) care pathways for the primary care physicians by University of Minnesota Physicians Heart, October, 2011 Evaluation by the primary care physician: 1. Comprehensive history and
More informationAtrial Fibrillation Cardiac rate control or rhythm control could be the key to AF therapy
Cardiac rate control or rhythm control could be the key to AF therapy Recent studies have proven that an option of pharmacologic and non-pharmacologic therapy is available to patients who suffer from AF.
More informationAtrial Fibrillation The Basics
Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,
More informationAtrial Fibrillation Management Across the Spectrum of Illness
Disclosures Atrial Fibrillation Management Across the Spectrum of Illness NONE Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University Objectives AF Discuss the pathophysiology, diagnosis,
More informationTABLE 1 Clinical Classification of AF. New onset AF (first detected) Paroxysmal (<7 days, mostly < 24 hours)
Clinical Practice Guidelines for the Management of Patients With Atrial Fibrillation Deborah Ritchie RN, MN, Robert S Sheldon MD, PhD Cardiovascular Research Group, University of Calgary, Alberta Partly
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationManaging the Patient with Atrial Fibrillation
Pocket Guide Managing the Patient with Atrial Fibrillation Updated April 2012 Editor Stephen R. Shorofsky, MD, Ph.D. Assistant Editors Anastasios Saliaris, MD Shawn Robinson, MD www.hrsonline.org DEFINITION
More informationAtrial Fibrillation The High Risk Obese Patient
Atrial Fibrillation The High Risk Obese Patient Frederick Schaller, D.O.,F.A.C.O.I. Professor and Vice Dean Touro University Nevada A 56 year old male with a history of hypertension and chronic stable
More informationATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation
More informationPRACTICAL APPROACH TO SVT. Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia
PRACTICAL APPROACH TO SVT Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia CONDUCTION SYSTEM OF THE HEART SA node His bundle Left bundle AV node Right
More informationAtrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationAtrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015
Atrial Fibrillation: Drugs, Ablation, or Benign Neglect Robert Kennedy, MD October 10, 2015 Definitions 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary.
More informationAtrial fibrillation. Quick reference guide. Issue date: June 2006. The management of atrial fibrillation
Quick reference guide Issue date: June 2006 Atrial fibrillation The management of atrial fibrillation Developed by the National Collaborating Centre for Chronic Conditions Contents Contents Patient-centred
More informationAtrial Fibrillation. Management of Patients With. ACCF/AHA Pocket Guideline
ACCF/AHA Pocket Guideline Management of Patients With Atrial Fibrillation (Adapted from the 2006 ACC/AHA/ESC Guideline and the 2011 ACCF/AHA/HRS Focused Updates) 2011 American College of Cardiology Foundation
More informationNational Medicines Information Centre
National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie THE CONTEMPORARY MANAGEMENT OF ATRIAL FIBRILLATION VOLUME 12 NUMBER 3 2006
More informationPalpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust
Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationAtrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center
Atrial Fibrillation Based on ESC Guidelines Moshe Swissa MD Kaplan Medical Center Epidemiology AF affects 1 2% of the population, and this figure is likely to increase in the next 50 years. AF may long
More informationCurrent Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose
Current Management of Atrial Fibrillation Mary Macklin, MSN, APRN Concord Hospital Cardiac Associates DISCLOSURES I have no financial conflicts to disclose Book Women: Fit at Fifty. A Guide to Living Long.
More informationAddendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter
22 July 2010 EMA/CHMP/EWP/213056/2010 Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter Draft Agreed by Efficacy Working Party July 2008 Adoption by CHMP for release
More informationProtocol for the management of atrial fibrillation in primary care
Protocol for the management of atrial fibrillation in primary care Protocol for the management of atrial fibrillation in primary care Contents Page no Definition 2 Classification of AF 2 3 Identification
More informationACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY
Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationAtrial Fibrillation 2012: Latest Approaches to Diagnosis, Treatment, and Stroke Prevention
Atrial Fibrillation 2012: Latest Approaches to Diagnosis, Treatment, and Stroke Prevention Michael G. Clark, PA-C, MPAS, Ph.D., AACC Fisher Cardiology and Electrophysiology Bedford, Texas Disclosures Speakers
More informationAtrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
More informationThese guidelines have been withdrawn
These guidelines have been withdrawn MOH clinical practice guidelines are considered withdrawn five years after publication unless otherwise specified in individual guidelines. Users should keep in mind
More informationNORTHERN NETWORK OF CARDIAC CARE GUIDELINES FOR THE DETECTION AND MANAGEMENT OF ATRIAL FIBRILLATION (AF)
NORTHERN NETWORK OF CARDIAC CARE GUIDELINES FOR THE DETECTION AND MANAGEMENT OF ATRIAL FIBRILLATION (AF) These notes should be read in conjunction with the summary algorithms July 2007 CONTENTS 1. Introduction
More informationAtrial Fibrillation: Manual of Clinical Guidelines
Atrial Fibrillation: Manual of Clinical Guidelines Table of Contents Table of Contents...1 Introduction...2 How to Use this Manual...3 Atrial Fibrillation: COMMON ELEMENTS OF CARE...4 Definitions...4 Controlling
More informationClassification (ACC/AHA/ESC 2006)
ATRIAL FIBRILLATION Atrial Fibrillation Atrial fibrillation is a common disorder which affects 0.4% of the general population. The risk increases sharply with age so that the lifetime prevalence of AF
More informationThe Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It?
The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It? Indiana Chapter-ACC 17 th Annual Meeting Indianapolis, Indiana October 19, 2013 Deepak Bhakta MD FACC FACP FAHA FHRS CCDS Associate
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationPractical Rate and Rhythm Management of Atrial Fibrillation
Practical Rate and Rhythm Management of Atrial Fibrillation pocket guide UPDATED FEBRUARY 2013 Adapted from the ACCF/AHA/HRS 2011 Focused Updates Incorporated into the ACC/AHA/ESC Guidelines for the Management
More informationDISCLOSURE. Atrial Fibrillation Management An Evidence-based Approach OBJECTIVES BACKGROUND AFFIRM 9/16/2015
Death (%) Mortality (%) 9/16/2015 DISCLOSURE Atrial Fibrillation Management An Evidence-based Approach Jonathon Adams, MD, FHRS Relevant Financial Relationship(s) None Off Label Usage None OBJECTIVES What
More informationEpisode 20 Atrial fibrillation Prepared by Dr. Lucas Chartier
Episode 20 Atrial fibrillation Prepared by Dr. Lucas Chartier Most common dysrhythmia seen in ED, and incidence increasing with ageing population Presentation Common presentations: younger patients often
More informationAtrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
More informationACUTE ATRIAL FIBRILLATION TREATMENT IN THE SURGICAL PATIENT
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationProjected Number of Adults With AF in the US. Review the growing incidence and importance of AF in the population
Atrial Fibrillation Troy E. Rhodes, MD, PhD Division of Cardiovascular Medicine, Electrophysiology Ohio State University Medical Center Learning Objectives Review the growing incidence and importance of
More informationManagement of Atrial Fibrillation in the Emergency Department
Management of Atrial Fibrillation in the Emergency Department Ref: Emergency Medicine Clinics of North America, 2005 Introduction AfAf is most common cardiac arrhythmia Sequelae: : range from none to devastating:
More informationManagement of Atrial Fibrillation in Heart Failure
Disadvantages of AV Junction Ablation Persistent AFib- no AV synchrony Ongoing risk of thromboembolism Life-long dependency on pacemaker Comparison of LA Ablation vs. AVN Ablation LA Ablation AVN Ablation
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationA 35 yo female presents increasing fatigue and shortness of breath for several days. She is found to be in atrial fibrillation.
Ryan G. Aleong Cardiology Department University of Colorado A 35 yo female presents increasing fatigue and shortness of breath for several days. She is found to be in atrial fibrillation. 1. Initiation
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationATRIAL FIBRILLATION IN THE 21 ST CENTURY TIMOTHY DOWLING, D.O. FAMILY PHYSICIAN
ATRIAL FIBRILLATION IN THE 21 ST CENTURY TIMOTHY DOWLING, D.O. FAMILY PHYSICIAN GOALS AND OBJECTIVES At The end of this talk you should understand: What is Atrial Fibrillation Causes of Atrial Fibrillation
More informationA randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation
A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation Gabriel Sayer Lay Abstract: Atrial fibrillation is a common form of irregular,
More informationHow to control atrial fibrillation in 2013 The ideal patient for a rate control strategy
How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy L. Pison, MD Advances in Cardiac Arrhythmias and Great Innovations in Cardiology - Torino, September 28 th 2013
More informationAtrial Fibrillation. Management Strategies Marc D. Schrode, D.O., F.A.C.C.,F.A.C.O.I.
Atrial Fibrillation Management Strategies Marc D. Schrode, D.O., F.A.C.C.,F.A.C.O.I. Atrial Fibrillation Estimated that 2.6 to 6.1 million people in the U.S. with Afib as of 2010 By 2050 it is expected
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationATRIAL FIBRILLATION AND ANAESTHESIA
ATRIAL FIBRILLATION AND ANAESTHESIA Dr AD Theron, SHO in Anaesthesia, Royal Devon and Exeter Hospital, Exeter, UK. E-mail: drabrietheron@yahoo.co.uk Atrial fibrillation (AF) is one of the commonest arrhythmias.
More informationNEW ONSET ATRIAL FIBRILLATION IN THE SURGICAL PATIENT
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationPresenter Disclosure Information
2:15 3 pm Managing Arrhythmias in Primary Care Presenter Disclosure Information The following relationships exist related to this presentation: Raul Mitrani, MD, FACC, FHRS: Speakers Bureau for Medtronic.
More informationNon-Valvular Atrial Fibrillation & Anticoagulation Therapy: An Actuarial Study of the Medicare Population
Non-Valvular Atrial Fibrillation & Anticoagulation Therapy: An Actuarial Study of the Medicare Population Prepared by: Milliman, Inc., NY Kathryn Fitch, RN, MEd Principal and Healthcare Management Consultant
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationACLS PHARMACOLOGY 2011 Guidelines
ACLS PHARMACOLOGY 2011 Guidelines ADENOSINE Narrow complex tachycardias or wide complex tachycardias that may be supraventricular in nature. It is effective in treating 90% of the reentry arrhythmias.
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationTraditionally, the goal of atrial fibrillation (AF)
358 Clinical Pharmacist November 2010 Vol 2 Treatment of atrial fibrillation usually involves controlling ventricular rate or restoring sinus rhythm. Equally important is thromboembolic risk assessment
More informationRUSSELLS HALL HOSPITAL EMERGENCY DEPARTMENT
RUSSELLS HALL HOSPITAL EMERGENCY DEPARTMENT CLINICAL GUIDELINE ATRIAL FIBRILLATION March 2011 For quick links to AF algorithms: UNSTABLE PATIENT STABLE PATIENT - 1 - Introduction Atrial fibrillation is
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationNew Approaches to Anticoagulation in Atrial Fibrillation
New Approaches to Anticoagulation in Atrial Fibrillation Hugh Calkins M.D. Nicholas J. Fortuin Professor of Cardiology Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions
More informationATRIAL FIBRILLATION: Scope of the Problem. October 2015
ATRIAL FIBRILLATION: Scope of the Problem October 2015 Purpose of the Presentation Review the worldwide incidence and prognosis associated with atrial fibrillation (AF) Identify the types of AF, clinical
More informationAtrial Fibrillation: Rate Control Strategies
Atrial Fibrillation: Rate Control Strategies Olshansky, Brian Sbaity, Salam Summary The safest long-term management strategy for elderly patients with persistent or permanent and some patients with paroxysmal
More informationUpdates to the Alberta Drug Benefit List. Effective January 1, 2016
Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationAn Introduction to Tachyarrhythmias R. A. Seyon MN, NP, CCN(C) & Dr. R. G. Williams
Arrhythmias 1 An Introduction to Tachyarrhythmias R. A. Seyon MN, NP, CCN(C) & Dr. R. G. Williams Things to keep in mind when analyzing arrhythmias: Electrical activity recorded in 12 and 15 leads Examine
More informationPractical Management of Atrial Fibrillation
Practical Management of Atrial Fibrillation UPDATED JULY 2014 Adapted from the AHA/ACC/HRS 2014 Guideline for the Management of Patients with Atrial Fibrillation Editor: Bradley P. Knight, MD, FACC, FHRS
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationRate Control vs Rhythm Control in Patients With Nonvalvular Persistent Atrial Fibrillation*
Rate Control vs Rhythm Control in Patients With Nonvalvular Persistent Atrial Fibrillation* The Results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study Grzegorz Opolski, MD, PhD;
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationGUIDELINE 11.9 MANAGING ACUTE DYSRHYTHMIAS. (To be read in conjunction with Guideline 11.7 Post-Resuscitation Therapy in Adult Advanced Life Support)
AUSTRALIAN RESUSCITATION COUNCIL GUIDELINE 11.9 MANAGING ACUTE DYSRHYTHMIAS (To be read in conjunction with Guideline 11.7 Post-Resuscitation Therapy in Adult Advanced Life Support) The term cardiac arrhythmia
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationWhat Should be the Primary Treatment in Atrial Fibrillation: Ventricular Rate Control or Sinus Rhythm Control with Long-term Anticoagulation?
The Journal of International Medical Research 2009; 37: 464 471 What Should be the Primary Treatment in Atrial Fibrillation: Ventricular Rate Control or Sinus Rhythm Control with Long-term Anticoagulation?
More informationNAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3
1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications
More informationAtrial & Junctional Dysrhythmias
Atrial & Junctional Dysrhythmias Atrial & Junctional Dysrhythmias Atrial Premature Atrial Complex Wandering Atrial Pacemaker Atrial Tachycardia (ectopic) Multifocal Atrial Tachycardia Atrial Flutter Atrial
More informationCOVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION
COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION Question: How should the EGBS Coverage Guidance regarding ablation for atrial fibrillation be applied to the Prioritized List? Question source: Evidence
More informationUnrestricted grant Boehringer Ingelheim
ED Management of Recent Onset tat Atrial Fibrillation and Flutter (RAFF) Canadian Cardiovascular Society Guidelines 2010 CAEP St John s 2011 Ian Stiell MD MSc FRCPC Professor and Chair, Dept of Emergency
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationDifficult Cases in Atrial Fibrillation. Ascot Cardiology GP Symposium April 2014
Difficult Cases in Atrial Fibrillation Ascot Cardiology GP Symposium April 2014 Atrial Fibrillation 1-2% general population 40-50yrs
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationIntroduction 2/9/2015
Thomas Haffey, D.O. FACC, FACOI, FNLA, CSOM February, 2015 Atrial Tachycardias Diagram summarizing types of atrial tachycardias often encountered in patients with a history of AF, including those seen
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationManagement of. Atrial. Inpatient. for the acute care. patient s discharge. Clinical Presentation Patients presenting be evaluated. for AF/AFL.
Guidelines for Clinical Care Inpatient Atrial Fibrillation Guideline Team Team Members Jeffrey M Rohde, MD (Team Lead) Internal Medicine Sarah E Hartley, MD Internal Medicine Sarah Hanigan, PharmD Pharmacy
More informationHTEC 91. Topic for Today: Atrial Rhythms. NSR with PAC. Nonconducted PAC. Nonconducted PAC. Premature Atrial Contractions (PACs)
HTEC 91 Medical Office Diagnostic Tests Week 4 Topic for Today: Atrial Rhythms PACs: Premature Atrial Contractions PAT: Paroxysmal Atrial Tachycardia AF: Atrial Fibrillation Atrial Flutter Premature Atrial
More informationReview. Management of atrial fibrillation
Lancet 2007; 370: 604 18 University Department of Medicine, City Hospital, Birmingham, UK (Prof G Y H Lip MD); and Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, China
More informationATRIAL FIBRILLATION. Michael Diamant and Luke Rannelli Internal Medicine PGY-3
ATRIAL FIBRILLATION Michael Diamant and Luke Rannelli Internal Medicine PGY-3 OBJECTIVES Guidelines-based approach to the following: Initial diagnosis and work-up Management as an outpatient Rate control
More informationAtrial Fibrillation in the ICU: Attempting to defend 4 controversial statements
Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationINFORMATION FOR PATIENTS AND FAMILIES A Patient s Guide to Living with Atrial Fibrillation
INFORMATION FOR PATIENTS AND FAMILIES A Patient s Guide to Living with Atrial Fibrillation 30 Bond Street, Toronto, ON M5B 1W8 Canada 416.864.6060 stmichaelshospital.com Form No. XXXXX Dev. XX/XXXX GOALS
More informationAtrial Fibrillation : Present Treatment Protocols by Drugs and Interventions
UPDATE ARTICLE JIACM 2003; 4(3): 213-27 Atrial Fibrillation : Present Treatment Protocols by Drugs and Interventions Indranill Basu Ray* Abstract Atrial fibrillation is the commonest arrhythmia encountered
More informationin the clinic Atrial Fibrillation in the clinic Diagnosis Treatment Practice Improvement CME Questions page ITC5-2 page ITC5-6 page ITC5-14
Section Editors Christine Laine, MD, MPH David Goldmann, MD Physician Writer David J. Callans, MD in the clinic Atrial Fibrillation Diagnosis Treatment Practice Improvement CME Questions page ITC5-2 page
More informationA focus on atrial fibrillation
A focus on atrial fibrillation Is being female really a risk factor for stroke? Dr Justin Mariani MBBS BMedSci PhD FRACP FCSANZ Consultant Cardiologist and Interventional Heart Failure Specialist Alfred
More informationCardioversion for. Atrial Fibrillation. Your Heart s Electrical System Cardioversion Living with Atrial Fibrillation
Cardioversion for Atrial Fibrillation Your Heart s Electrical System Cardioversion Living with Atrial Fibrillation When You Have Atrial Fibrillation You ve been told you have a heart condition called atrial
More information